Overview

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Status:
Completed
Trial end date:
2017-08-15
Target enrollment:
0
Participant gender:
All
Summary
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ocular Technologies SARL
Sun Pharma Global FZE
Criteria
Inclusion Criteria:

- Completion of Study OTX-101-2016-001

Exclusion Criteria:

-